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ABSTRACT 
Influenza is a segmented negative strand RNA virus. Each RNA segment 
is encapsulated by viral nucleoprotein (NP) and bound by the viral RNA 
dependent RNA polymerase (RdRP) to form viral ribonucleoproteins (vRNPs) 
responsible for RNA synthesis. NP is a structural component of the vRNP but 
also interacts with both viral and host factors to regulate viral RNA expression. 
NP is conserved among influenza A isolates, making NP interactions compelling 
antiviral targets. Here I characterize mutations within 5 amino acids of NP that 
comprise an accessible region of the NP body domain, as determined by NP 
crystal structure. This region was selected for mutagenesis to target interaction 
between NP and RdRP.  
NPbd3 encodes glycine at 5 amino acids within the accessible NP body 
domain. Cellular fractionation and Western Blot, in addition to NP-GFP fusions 
and fluorescence, confirm NPbd3 was expressed and localized as WT-NP. Gel 
shift with purified NP protein confirm NPbd3 bound nucleic acids as WT-NP. 
Although NPbd3 was expressed, localized, and bound nucleic acid as WT-NP, I 
found NPbd3 was defective for RNA expression in reconstituted vRNPs, as 
evaluated by reverse transcription and quantitative polymerase chain reaction 
(RT-qPCR). To investigate this NP body domain further, single and double amino 
acid mutations were cloned. Analysis of NP single mutants revealed that all were 
nearly as functional as WT-NP for RNA expression in reconstituted vRNPs, 
suggesting these accessible amino acids in the NP body domain play a 
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redundant role. However, four different combinations of two amino acid mutations 
resulted in NP double mutants that displayed a significant defect in RNA 
expression in reconstituted vRNPs, confirming these accessible amino acids in 
the NP body domain play a significant role for viral RNA synthesis.  
A disruption in an essential NP interaction with the RdRP is likely the 
explanation for the RNA defect observed. In support of this, avian influenza virus 
passaged in human cells resulted in virus with one NP amino acid change in this 
domain consistently paired with specific changes in the PB2 subunit of the RdRP. 
I reason this accessible body domain of NP is a viable antiviral target. Indeed, 
two amino acids in this NP body domain comprise a novel groove implicated in 
binding the small molecule inhibitor nucleozin. My thesis highlights this 
conserved NP body domain as an important interaction surface essential for viral 
RNA synthesis and support further investigation of antiviral drugs that target this 
region of NP. 
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CHAPTER ONE 
EMERGING ANTIVIRAL RESISTANT STRAINS OF INFLUENZA A AND THE 
POTENTIAL THERAPEUTIC TARGETS WITHIN THE VIRAL 
RIBONUCLEOPROTEIN (VRNP) COMPLEX 
Background 
This chapter is copied in whole from Davis et al.: Emerging antiviral resistant 
strains of influenza A and the potential therapeutic targets within the viral 
ribonucleoprotein (vRNP) complex. Virology Journal 2014 11:167. 
Influenza A viruses are infectious agents spread through contact or 
aerosol droplets that result in a seasonal respiratory illness which can potentially 
lead to death. Highly transmissible influenza A viruses can reach pandemic 
proportions as seen in 1918, 1957, 1968, and 2009. The natural reservoir for 
influenza A viruses are aquatic birds, but many animals are susceptible to 
infection, including swine and humans. While humans are not readily infected 
with avian influenza viruses, in rare cases direct avian to human transmission 
has occurred. Swine are readily susceptible to avian, swine, and human 
influenza subtypes and provide a vessel for genome reassortment among 
different subtypes of the virus. The influenza A virus genome is made up of eight 
negative sense RNA segments (vRNA). Reassortment of genome segments 
between different influenza A subtypes can yield new influenza A subtypes that 
have potential to cause a human influenza pandemic. While the 1918 pandemic 
virus was found to be of wholly avian origin, the 1957 and 1968 pandemics 
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contained segments of avian and human origin (Reid and Taubengerger, 2003). 
In this case it is unclear if swine or human were the vessel of reassortment; 
although swine are more readily infected with avian influenzas, thus providing 
more opportunity for reassortment, humans can be infected with avian influenza, 
and although rare, reassortment within a human host remains a possibility (Reid 
and Taubengerger, 2003). The 2009 influenza H1N1 pandemic contained 
segments of avian, swine, and human origin and was thus a triple reassortant 
that likely emerged from swine (Neumann et al., 2009). 
Influenza infection is typically prevented by annual vaccination. However, 
vaccines are not useful after infection or against emerging subtypes of influenza 
not targeted during vaccine production, as witnessed with the novel H1N1 
pandemic in 2009. Therefore, antivirals that target specific proteins to inhibit virus 
replication are necessary to stave the spread of an emerging pandemic. The 
eight genome segments of influenza A virus encode 10 different coding mRNAs 
by way of alternate splicing (Dubois et al., 2014) which result in over 12 proteins 
due to alternate translation (Chen et al., 2001, Wise et al., 2009, Jagger et al., 
2012, Muramoto et al., 2012). Two viral segments code for the surface proteins 
HA and NA for which influenza subtypes are named. Three viral gene segments 
encode the RNA dependent RNA polymerase complex: PA, PB1, and PB2. At 
least two of these genome segments also encode alternate translation products 
including PB1-F2, PB1-N40, PA-X, PA-N155 and PA-N182 (Chen et al., 2001, 
Wise et al., 2009, Jagger et al., 2012, Muramoto et al., 2012). One segment 
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encodes the nucleoprotein NP. Two segments, M and NS, undergo alternate 
splicing to produce NS1, NS2 (NEP), M1 and M2 proteins. With so many viral 
protein interactions required in various stages of the influenza life cycle, there are 
numerous potential target sites for antiviral treatments. Current antivirals target 
the activities of M2 and NA, but resistance is emerging. This review catalogs the 
current state of influenza antiviral resistance and describes promising new 
molecules targeting proteins within the viral ribonucleoprotein (vRNP), the 
complex comprised of the viral RNA genome, the RNA-dependent RNA 
polymerase (RdRP), and nucleoprotein (NP).  
Current Antivirals and Resistance 
The current antivirals approved by the FDA are, in order of their release, 
Symmetra (amantadine), Flumadine (rimantadine), Relenza (zanamivir), and 
Tamiflu (oseltamivir). Amantadine and rimantandine are adamantane derivatives 
that target and inhibit the M2 ion channel. The M2 ion channel is an integral 
membrane protein responsible for release of vRNPs during infection (Pinto et al., 
1992). By binding to the M2 ion channel, amantadine and rimantandine inhibit 
vRNP release and thus viral replication (Hay et al., 1985, Jing et al., 2008). The 
antivirals zanamivir and oseltamivir are NA or neuraminidase inhibitors. NA 
activity is required to release new virions from infected cells (Davis et al., 1983). 
These drugs inhibit virus release from infected host cells by binding to the active 
site of the NA protein (Meindl et al., 1974, Palese and Compans, 1974).  
Resistance against both classes of influenza antiviral treatments has been 
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documented. Resistance to M2 ion channel inhibitors occurs via a triple amino 
acid deletion at residues 28-31 or single amino acid substitutions in the 
transmembrane region spanning residues 26-31 of the M2 protein (Holsinger et 
al., 1994, Abed et al., 2005). 100% of H3N2 influenza A viruses circulating in 
2009-2010 and 99.8% of 2009 pandemic H1N1 were resistant to adamantanes 
(CDC-1). Many resistant H1N1 isolates encoded V27A substitution, while 
resistant H3N2 isolates were found to encode substitutions at L26F, V27A, A30T, 
S31N, or G34E (Tang et al., 2008).  Resistance to adamantanes in H7N9 has 
also been documented and is acquired by substitution S31N (Chen et al., 2013).  
Resistance to NA inhibitors is less common as this class of inhibitors was 
developed later. For example, 98.9% of tested 2009 H1N1 viruses remained 
susceptible to oseltamivir, 100% of 2009 H1N1 viruses tested remained 
susceptible to zanamivir (CDC-2), 100% of influenza A (H3N2) tested remained 
susceptible to both oseltamivir and zanamivir for the 2012-2013 season (CDC-3). 
However, multiple single amino acid changes in NA alter susceptibility to the 
approved neuraminidase inhibitors. Residues V116, I117, E119, Q136, K150, 
D151, D199, I223, H275, and N295 were selected to monitor for changes that 
confer drug resistance or reduce efficacy of the antivirals (Deyde et al., 2010). 
Resistance evolves during treatment, via single amino acid substitutions 
including changes to amino acids mentioned above such as E119V I223R 
(Pizzorno et al., 2012, van der Vries et al., 2011), and H275Y (Baz et al., 2009), 
but also R292K and N294S (Kiso et al., 2004).  Pandemic H1N1 2009 isolates 
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with a substitution at I223R were resistant to neuraminidase inhibitors in addition 
to M2 ion channel inhibitors as discussed above (van der Vries et al., 2011). 
Thus, while NA inhibitors are currently still viable to combat most emerging 
influenza threats, it is only a matter of time before resistance takes hold as with 
the adamantanes, rendering both current antiviral therapies ineffective against an 
emerging influenza threat.  
Most worrisome is resistance reported among Highly Pathogenic Avian 
Influenza (HPAI) subtypes that could spur the next pandemic. Avian subtypes 
such as H5N1, H7N9, and H7N7 have all resulted in human infection. The H5N1 
infections result in high morbidity at ~60%, while H7N9 and H7N7 have seen 
more variability in outcome of human infection (WHO). Fortunately none of these 
subtypes have gained the ability to transmit readily from human to human, but 
unfortunately, these strains already have antiviral resistant isolates reported. For 
example, all H7N9 isolates tested were resistant to adamantanes via the S31N 
substitution in the M2 protein (Gao et al., 2013), while some H7N9 exhibit high 
resistance to oseltamivir, mid-resistance to peramivir, and low-resistance to 
zanamivir via the NA R292K substitution (Hai et al., 2013). Also of grave concern 
are H5N1 isolates that encode M2 changes to confer resistance to adamantanes 
and NA changes that reduce susceptibility to neuraminidase inhibitors (Hurt et 
al., 2007).  With many circulating antiviral resistant strains and the consequences 
of a looming virulent influenza pandemic, novel antiviral targets must be 
investigated so that new therapies can be developed before such a catastrophic 
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event occurs. One promising new viral target is the viral ribonucleoprotein or 
vRNP. Figure 1 depicts vRNP interactions and activities targeted by new anti-
influenza candidates. 
VRNP: Viral Ribonucleoprotein 
During infection eight vRNPs, containing the eight different vRNA genome 
segments, are released and imported into the nucleus to transcribe and replicate 
the vRNA. Transcription of the viral genome proceeds via a cellular capped-
mRNA primer cleaved from host mRNA by the viral polymerase (Plotch et al., 
1981). Unlike other RNA genome viruses, which typically replicate in the 
cytoplasm, influenza must enter the nucleus to steal nascent host capped 
mRNAs for use as primers in transcription. The polymerase subunit PA provides 
the endonuclease activity (Yuan et al., 2009, Dias et al., 2009), while PB2 
houses the active site where the host pre-mRNA will bind (33).  Polymerization of 
the viral mRNA transcript proceeds via the PB1 subunit until the polyadenylation 
signal of repetitive U residues result in stuttering by the viral RdRP and yields the 
poly(A) tail, terminating transcription (Poon et al., 1999). Transcripts of two 
influenza genome segments, M and NS, undergo alternative splicing to produce 
M1, M2, NS1 and NS2 (NEP); utilization of host nuclear splicing machinery is 
another reason for nuclear localization of influenza vRNPs. 
Viral replication occurs de novo, without a primer (Shapiro et al., 1988). In 
the host cell viral RNA replication occurs after translation of viral RdRP and NP 
proteins. Evidence suggests a model wherein the resident RdRP of the vRNP is 
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responsible for transcription, while a soluble RdRP is responsible for replication 
from the vRNA template (Jorba et al., 2009). There are two primer-independent 
steps of viral replication. First the vRNA template is used to synthesize a full-
length complementary (cRNA), which is then replicated to yield progeny vRNA 
that can be transcribed to mRNA or packaged into new virions during later stages 
of the viral replication cycle. NP is required for anti-termination at the poly U 
stretch to allow for replication of full length cRNA (Beaton and Krug, 1986). NP 
encapsidates both cRNA and vRNA replication products and is necessary for 
genome length functional cRNPs and vRNPs, respectively (Honda et al., 1988).  
NP: Nucleoprotein 
The crystal structure of NP (Ye et al., 2006) (Figure 2) reveals two regions 
termed the body domain and the head domain, between which lies a deep 
groove comprised of positively charged basic amino acid residues that form ionic 
bonds with the negatively charged phosphate backbone of viral cRNA and vRNA. 
On the opposing side of the RNA binding groove lies a tail loop for 
oligomerization with other NP monomers. The tail loop of NP spans residues 
402-428, and is critical to NP oligomerization and RNA binding, as shown 
through a tail loop deletion mutant that produced primarily monomeric NP unable 
to oligomerize and bind RNA (Ye et al., 2013). Another crucial oligomerization 
interaction occurs through a salt bridge between residue 339 of one NP 
monomer and residue 416 of another NP monomer (Ye et al., 2006, Kao et al., 
2009, Shen et al., 2011). Mutational studies disrupting this salt bridge led to 
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inhibition of viral RNA synthesis in vitro, further highlighting the importance of the 
interaction between NP molecules for vRNP function (Shen et al., 2011). 
However, NP is more than a structural RNA binding protein. NP 
associates with viral proteins such as PB1 and PB2 (Biswas et al., 1998), and M1 
(Avalos et al., 1997), in addition to several cellular factors (Portela and Digard, 
2002). Interaction between NP and the RdRP enhanced unprimed replication in 
vitro, suggesting the NP-RdRP interaction may regulate the switch from primer 
initiated transcription to unprimed replication (Newcomb et al., 2009). Interaction 
of NP with the polymerase subunits was crudely mapped to regions within both 
the body and head domain of the NP crystal structure (Biswas et al., 1998, Ye et 
al., 2006). NP-PB2 and NP-PB1 associations were confirmed through co-
immunoprecipitation assays in the absence of other viral factors (Biswas et al., 
1998). The NP-PB2 interaction was refined to residue 627 and 630 of PB2 and 
residue 150 of NP, with the strength of NP-PB2 interaction directly correlated 
with RdRP activity (Ng et al., 2012). Residue R150 of NP is highly conserved and 
vital for normal viral RNA synthesis during influenza A WSN infection of MDCK 
cells (Li et al., 2009). As discussed below, PB2 residue 627 is a well-
characterized host range determinant (Subbarao et al., 1993, Kuzuhara et al., 
2009). Additional NP mutational analysis revealed alanine substitutions within 
three residues of the head domain at 204, 207, and 208 disrupt interaction with 
the viral polymerase and inhibit viral RNA synthesis (Marklund et al., 2012). 
Cryo-EM and cryo-electron tomography data of native vRNPs in packaged 
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virions revealed two different conformations of polymerase interaction with NP 
within the vRNP (Arranz et al., 2012). Together, the evidence points to multiple 
residues on NP that participate in NP-RdRP interactions. The protein sequence 
homology of NP is a staggering ninety percent among influenza A isolates 
(Gorman et al., 1990), with the described interaction domains exhibiting even 
greater homology, highlighting the potential of disrupting NP interactions as an 
effective antiviral target. 
RdRP: RNA Dependent RNA Polymerase 
The influenza A virus RNA dependent RNA polymerase is a heterotrimer 
comprised of PA, PB2, and PB1.  
PA. While PA is required for both viral transcription and replication, the 
major role attributed to PA during influenza infection is the endonuclease activity 
needed to steal capped primers for viral transcription initiation in the nucleus of a 
host cell (Plotch et al., 1981, Yuan et al., 2009, Dias et al., 2009, Zhao et al., 
2009). Several highly conserved endonuclease active sites span the N-terminal 
209 residues of PA (Dias et al., 2009). Alanine screening of amino acids 102 
through 134 revealed residues necessary for endonuclease activity (Hara et al., 
2006). Substitutions D108A and K134A individually inhibited both endonuclease 
activity and transcription in vitro (Yuan et al., 2009, Hara et al., 2006). PA also 
makes contacts with both vRNA and cRNA promoters between residues 100-
180, though the precise residues involved are debated (Hara et al., 2006, Deng 
et al., 2006, Maier et al., 2008). In addition, PA has documented protease activity 
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with Ser 624 defined as the active site (Hara et al., 2006), though the purpose of 
this activity remains poorly understood. The essential endonuclease activity of 
PA is an excellent target for antivirals.  
PB2. PB2 contains the cap-binding domain, which recognizes the capped 
structure on nascent host mRNAs to be cleaved by the endonuclease site of PA 
(Li et al., 2001). PB2 residues 318-483 comprise this domain and contain two 
aromatic amino acids at positions 363 and 404 necessary for cap-binding 
(Fetcher et al., 2003, Guilligay et al., 2008). The cap-binding domain of PB2 may 
also mediate interaction between PB1 and PB2, specifically a loop consisting of 
residues 421-427 of PB2, which is essential for cap-dependent transcription but 
not cap-binding, as determined by a deletion mutant (Guiligay et al., 2008). Cap-
binding and capped RNA primed transcription are essential activities for influenza 
that can be targeted by novel antivirals.  
PB2 also makes contacts with both vRNA and cRNA promoters in an 
alpha helix rich region between residues 535-684, which form an RNA binding 
domain (Kuzuhara et al., 2009). Located within this domain is residue 627, a 
well-characterized species and pathogenicity determinant for influenza A viruses 
(Subbarao et al., 1993, Kuzuhara et al., 2009, Massin et al., 2001, Shinya et al., 
2004, Labadie et al., 2007, Tarendeau et al., 2008). Avian influenza A viruses 
encode PB2 with glutamic acid at residue 627, while human influenza A viruses 
encode lysine (Subbarao et al., 1993). RNA binding ability of PB2 was linked to 
the amino acid encoded at 627, with increased RNA binding shown for PB2 
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proteins containing 627K (Kuzuhara et al., 2009). Polymerase activity and 
interaction of PB2 with NP were also shown to be influenced by PB2 residue 627, 
in addition to residue 630 (Ng et al., 2012). Characteristic avian PB2 residue 
E627 must also encode R630 for proper polymerase activity and co-
immunoprecipitation with NP (Ng et al., 2012). Characteristic human PB2 residue 
K627 requires G630 for proper polymerase activity and co-immunoprecipitation 
with NP (Ng et al., 2012). Residue 627 of PB2 influences binding of NP and 
RNA, two interactions essential for viral RNA synthesis, making this region of 
PB2 a favorable target for new antivirals.  
PB1. PB1 is the RNA polymerizing subunit of the RNA dependent RNA 
polymerase. Residues 1-83 and 494-757 of PB1 contribute to vRNA template 
interaction through in vitro analysis of PB1 deletion mutants (González et al., 
1999). PB1 interacts with PA through its N terminal domain and PB2 through its 
C terminal domain, thus forming the functional RNA dependent RNA polymerase 
(Perez and Donis, 1995, González et al., 1996, Perez et al., 2001, He et al., 
2008). RNA dependent RNA polymerase activity of RNA viruses represents a 
viral activity that can be targeted by antivirals.  
The C-terminal domain of PB1 (678-757) and the N-terminal domain of 
PB2 (1-37) were defined as the regions responsible for PB1-PB2 interaction and 
were crystalized to facilitate further investigation (González et al., 1996, 
Sugiyama et al., 2009). Crystal structure of this interaction reveals all contacts 
occur through helix 1 of PB2 (residues 1-12), which is essential for proper RNA 
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polymerase activity (Sugiyama et al., 2009). The PB1-PB2 protein interface is of 
great interest as an antiviral target due to the conservation of these domains in 
both human and avian viruses (Sugiyama et al., 2009).  
The N-terminus of PB1 (1-80) interacts with the C terminal region of PA 
consisting of residues 239-716 (González et al., 1996, Krug and Aramini, 2009). 
Interaction surfaces of both PB1 and PA are highly conserved (He et al., 2008, 
Wunderlich et al., 2009, Obayashi et al., 2008). The crystal structure of this 
interaction reveals PB1 N terminal 25 residues occupy a C-terminal hydrophobic 
groove of PA (68) (Figure 3). The C-terminal domain of PA has been referred to 
as a “dragon’s head” that holds the N-terminus of PB1 in its “jaws” (He et al., 
2008). A peptide analog of the N-terminal 25 amino acids of PB1 blocks 
formation of the RNA dependent RNA polymerase complex resulting in no viral 
replication (He et al., 2008, Ghanem et al., 2007). These studies demonstrate the 
critical interaction between PB1 and PA in the formation of the RNA dependent 
RNA polymerase heterotrimer vital for viral RNA synthesis, making this 
interaction a potential target for novel antivirals. 
New Antivirals Targeting Influenza A VRNP 
The critical roles of the influenza vRNP for viral RNA synthesis make 
activities of the vRNP, such as cap-snatching and RNA polymerization, excellent 
antiviral targets. A recently discovered nucleotide analog preferentially utilized by 
viral RNA dependent RNA polymerases including influenza vRNP, is under study 
as a promising antiviral therapy targeting the activity of viral RNA dependent 
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RNA polymerases (Furuta et al., 2002). Further, the multiple essential 
interactions of the vRNP, such as with each other to form the RNA dependent 
RNA polymerase heterodimer, with host capped mRNAs to obtain primers for 
viral transcription, and with NP to regulate and enhance RNA replication, coupled 
with high conservation of these domains among influenza subtypes, make the 
proteins of the vRNP excellent targets for small molecule inhibitors with broad 
efficacy against multiple influenza A subtypes.   
Ribonucleotide Analogs 
Favipiravir is a 6-fluoro-3-hydroxy-2-pyrazinecarboxamide molecule (also 
known as T-705) that upon phosphorylation becomes favipiravir-ribofuranosyl-5’-
triphosphate (RTP) and inhibits many viral RNA dependent RNA polymerases 
(75). Favipiravir is effective against influenza A, influenza B, influenza C, 
hantaviruses, flaviviruses, noroviruses, and most recently ebola viruses (Furuta 
et al., 2002, Furuta et al., 2013, Oestereich et al., 2014). The T-705 RTP is 
erroneously interpreted as a purine nucleotide by the viral polymerase during 
RNA elongation (Furuta et al., 2013, Jin et al., 2013). Once incorporated into the 
elongating viral RNA, the analog may hinder strand extension (Jin et al., 2013). 
The antiviral activity of Favipiravir includes influenza A(H3N2), A(H1N1), 
A(H5N1), A(H7N9), and strains bearing resistance to both classes of the current 
FDA approved influenza antivirals (Furuta et al., 2002, Furuta et al., 2013, 
Sleeman et al., 2010).  
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The 50% inhibitory concentration (IC50) of favipiravir for influenza, 
determined by plaque reduction assay, was 0.013-0.48 µg/ml with no cytotoxic 
effect up to 1000 µg/ml (Furuta et al., 2002). Human DNA polymerase α, β, or γ 
with 1000 µM of favipiravir showed little sign of inhibition (Kiso et al., 2010) and 
human RNA polymerase II had an IC50 of 905 µM of favipiravir (Takahashi et al., 
2011). Therefore, the IC50 of host polymerases is well over 2000 times greater 
then the IC50 for influenza vRNP, making favipiravir highly selective for influenza 
vRNP (Furuta et al., 2013). Favipiravir for influenza therapy has finished two 
Phase II clinical trials in the United States and one Phase II clinical trial in Japan 
(Furuta et al., 2013). Favipiravir is a favorable candidate for a broadly effective 
antiviral therapy targeting RNA viruses with RNA dependent RNA polymerases 
that preferentially incorporate favipiravir in RNA synthesis.  It is not yet clear if or 
how quickly influenza vRNP will evolve resistance to this nucleotide analog, but 
based on HBV and approved nucleotide analog therapies (Menéndez-Arias et al., 
2014), as with any antiviral therapy, if resistance is possible, it will eventually 
develop, stressing the need to consistently look for novel antiviral targets and 
therapies.   
Small Molecule Inhibitors 
Unlike nucleotide analog therapies, small molecule inhibitors work by 
interaction with a viral protein to block a function or interaction and inhibit viral 
replication. Crystal structure data provides much information to identify small 
molecules with potential to bind a domain of the target protein and inhibit 
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essential functions or interactions. Small molecules that target conserved regions 
are likely to have the best efficacy against multiple subtypes. Further, conserved 
regions are less likely to tolerate mutation and evolve a viable virus with 
resistance to the small molecule. 
Targeting NP 
Nucleozin is a small molecule inhibitor of NP that works by promoting NP 
oligomerization, blocking nuclear entry through aggregation of NP molecules at 
the nuclear membrane (Kao et al., 2010) and inducing vRNP aggregation during 
cytoplasmic trafficking (Amorim et al., 2013). Molecular docking models identified 
two proposed nucleozin interaction sites at residue 289 and 309 of NP (Kao et 
al., 2010). Both residues participate to stabilize the interaction; a tyrosine at 
residue 289 forms aromatic ring stacking with nucleozin, while an asparagine at 
residue 309 shares a hydrogen bond with nucleozin. Strains found to be 
nucleozin resistant encoded a histidine in place of a tyrosine at residue 289 of 
NP (Kao et al., 2010). From the crystal structure of NP, residue 289 is relatively 
accessible to interact with nucleozin (Figure 2) (39, Kao et al., 2010). The 289H 
NP variant likely disrupts a critical point of interaction between NP and nucleozin. 
Sequence analysis of the NP gene of 3,881 influenza strains revealed Y289H 
substitution in 527 strains. Unfortunately the A(H1N1)pdm09 strain was shown to 
contain this single amino acid alteration, signifying it as a nucleozin resistant 
strain (Kao et al., 2010). Nucleozin demonstrated a 50% effective concentration 
(EC50) of only 0.069 µM against influenza with 50% cytotoxic concentration 
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greater than 250 µM (Kao et al., 2010). Thus nucleozin still holds potential as a 
potent antiviral for strains of influenza housing a tyrosine at residue 289 (Kao et 
al., 2010). In addition to nucleozin, there are several other aryl piperazine amide 
compounds discovered in parallel that target NP and inhibit virus replication in 
the same manner (Kao et al., 2010, Su et al., 2010, Gerritz et al., 2011, Cianci et 
al., 2013). Cianci et al. provide a detailed review into the efficacy of aryl 
piperazine amides, including nucleozin, as NP inhibitors (Cianci et al., 2013). 
Further analysis of these compounds could lead to the synthesis of an optimized 
aryl piperazine amide inhibitor of viral replication, even against the circulating 
nucleozin resistant strains of influenza.  
The essential salt bridge for NP oligomerization at residues 339 and 416 
was targeted for disruption by small molecule inhibitors (Figure 2) (Shen et al., 
2011). Peptides that mimicked the NP tail loop (residues 402-428) bound in the 
tail loop binding pocket and inhibited NP oligomerization, resulting in decreased 
viral replication by greater than fifty percent (Shen et al., 2011). Random virtual 
screening of small molecules identified four compounds (termed # 3, 7, 12, and 
23) that interrupt NP oligomerization and decrease viral replication (Shen et al., 
2011). The IC50 of compounds 3, 7, 12, and 23 ranged from 2.4 to 118 µM in 
cells challenged with influenza A/WSN/33 for nine hours at a multiplicity of 
infection (MOI) of 0.2 (Shen et al., 2011). Although the targeted NP domain is 
highly conserved, more research will need to be carried out to ensure little to no 
development of resistance to the compounds. Importantly, cytotoxicity of these 
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compounds will need to be assessed before they can be of use as antiviral 
therapies.  
Mycalamide A is an antiviral and antitumor compound isolated from 
Mycale sponges but is unfortunately toxic to cells (Perry et al., 1988). A photo-
cross-linked chemical array identified analogs of mycalamide A that possess the 
ability to bind NP (Hagiwara et al., 2010). One compound inhibited viral 
replication up to 77% in a plaque assay using influenza virus (A/WSN/33) with no 
cytotoxic effect (Hagiwara et al., 2010). Binding affinity of the analogs was 
greatest within the N-terminal 110 amino acids of NP (Hagiwara et al., 2010). 
Although the mechanism of inhibition remains uncharacterized, the N-terminus of 
NP contains an important non-canonical nuclear localization signal (NLS) (Wang 
et al., 1997, Cros et al., 2005) and interacts with host RNA processing factors 
UAP56 and URH49 (Momose et al., 2001, Wisskirchen et al., 2011) proposed to 
enhance RNA replication (Kawaguchi et al., 2011). More research is needed on 
these compounds to elucidate the mechanism of inhibition and determine if or 
how quickly influenza NP will evolve resistance.  
Naproxen is an over the counter nonsteroidal anti-inflammatory drug that 
inhibits NP from associating with RNA in the RNA binding groove (Figure 2) 
(Lejal et al., 2013). From several molecular docking studies, residues Y148, 
Q149, R150, R355, R361, and F489 are believed to stabilize naproxen binding to 
NP (Lejal et al., 2013). Naproxen acts selectively upon monomeric NP and was 
shown to protect MDCK cells and mice from a viral challenge at an MOI of 10-2 - 
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10-3 or 50 - 2,000 PFU respectively, with little to no cytotoxic effects (Lejal et al., 
2013). Subtypes of H1N1 and H3N2 were both susceptible to inhibition and 
treatment resulted in efficient protection from viral challenge with either subtype 
(Lejal et al., 2013). No escape mutant viruses were produced in response to 500 
µM naproxen treatment in cells after six passages (Lejal et al., 2013). Within this 
experiment the mode of delivery for naproxen was intraperitoneal injection or 
intranasal treatment in mice that displayed an EC50 of 40mg/kg (Lejal et al., 
2013). Naproxen is currently used as an oral medication with a recommended 
dosage of 220 mg every 8 hours for pain. Naproxen is not currently used as an 
antiviral but could be optimized for antiviral use through further experimentation 
and improved drug design. 
Targeting PA-PB1 Interaction 
Inhibitors of the PA-PB1 interaction are numerous (Muratore et al., 2012). 
Compound 1 was discovered through in silico screening (Muratore et al., 2012) 
using the crystal structure of PAC-PB1N (Figure 3) (He et al., 2008). The 
hydrophobic pocket of PA houses compound 1 according to molecular docking 
studies, and inhibition of PA-PB1 interaction was demonstrated through ELISA 
and immunoprecipitation of PA (Muratore et al., 2012). Compound 1 inhibited 
RNA polymerase activity in a dose-dependent manner with an IC50 of about 18 
µM assessed in a minireplicon assay using a firefly luciferase reporter gene, with 
no significant cytotoxic effect up to concentrations of 250-1000 µM (Muratore et 
al., 2012). Compound 1 inhibited viral replication in MDCK cells for several 
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influenza A H1N1 and H3N2 strains, a swine-origin influenza virus, and an 
oseltamivir-resistant isolate, with IC50 ranging from 12.2 to 22.5 µM (Muratore et 
al., 2012).  
There are two FDA approved medications that in addition to their intended 
use also possess anti-IAV abilities due to their structural similarity with the N 
terminal domain of PB1 that interacts with the C-terminus of PA (Figure 3) 
(Fukuoka et al., 2012). Benzbromarone is approved to treat gout and 
hyperuricemia by promoting the excretion of uric acid. Diclazuril is most 
commonly used in veterinary medicine as an anti-coccidial. Although these drugs 
are FDA approved, appropriate drug dosages for use against viral challenges 
would need to be established before they could be employed for use against 
influenza A. Testing for the ability of viruses to gain resistance to these drugs 
must also be done. Benzbromarone and diclazuril could potentially be utilized if 
an influenza strain arises that possesses resistance to other antivirals available 
(Fukuoka et al., 2012).  
In addition, a compound derived from licorice, 18β-glycyrrhetinic acid 
(GHA), is a naturally occurring compound that exhibits some anti-IAV activity 
attributed to interaction with the C terminal domain of PA (Li et al., 2012). 
Molecular docking studies identified GHA as a ligand to PAC (Li et al., 2012). 
GHA decreased polymerase activity 80%, as assessed by a primer extension 
assay for cRNA synthesis (Li et al., 2012). These preliminary findings need to be 
investigated further with more informative assays including in vitro PA-PB1 
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interaction inhibition study, in vivo polymerase activity assays in tissue culture, 
and in vivo infection in an animal model. There are many small molecules that 
mimic the N terminus of PB1 fit in the hydrophobic groove of PA to inhibit PA-
PB1 interaction (Figure 3) and should be studied further for their potential as an 
anti-influenza A treatment.  
Targeting PA Endonuclease 
Fullerene (C60) is a spherical molecule of sixty carbon atoms that exhibits 
anti-influenza activity (Shoji et al., 2013). Full length PA and an isolated PA 
endonuclease domain were tested in an in vitro endonuclease assay in the 
presence of fullerene derivatives. Seven fullerene derivatives were able to inhibit 
the endonuclease ability of the full length PA and isolated endonuclease domain 
(Shoji et al., 2013). Docking simulations reveal the fullerene skeleton fits nicely 
into the endonuclease domain active pocket (Shoji et al., 2013). MDCK cells 
were infected with influenza A H1N1 or H3N2 mixed with 0 to 100 µM fullerene 
derivative and immunostained for NP at 24 hours post infection to reveal 
significantly less NP in cells infected with virus pre-incubated with fullerene 
compared to a DMSO control (Shoji et al., 2013). Twelve derivatives of fullerene 
were tested and resulted in varying efficacy against influenza but showed no 
cytotoxic effect up to 100 µM (Shoji et al., 2013). More investigation into the 
activity and expression of viral proteins in response to fullerene needs to be 
conducted. Importantly, treatment applied post-infection needs to be 
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investigated. This novel compound exemplifies yet another possible antiviral 
target within the vRNP.  
Targeting PB2 Cap-binding Domain 
Compounds that mimic the 7-methylguanosine moiety of the 5’ cap of 
mRNAs may serve as transcriptional inhibitors. Docking studies of the cap-
binding domain of PB2 revealed 7-alkylguanine derivatives as potential inhibitory 
compounds (Pautus et al., 2013). Several compounds bind the cap-binding 
domain of PB2 with greater affinity than a biotinylated cap analogue (Pautus et 
al., 2013). These compounds should be further studied and optimized for anti-
influenza activity. 
Conclusion 
Influenza A virus continues to remain a human menace, in terms of both 
human health and global economic costs. The wide host range of influenza A 
virus, coupled with a lack of proofreading activity within the viral RNA dependent 
RNA polymerases, and a segmented RNA genome allowing for segment 
reassortment, provide influenza A virus with the ability to evolve rapidly. While 
yearly vaccination is protective against the strains and subtypes predicted to be 
circulating and represented during vaccine production, vaccination will not protect 
against an unseen, emerging subtype of the virus. Antivirals are the first line of 
defense for an emerging pandemic and resistance to current antivirals is already 
circulating within influenza A viruses, hastening the resolve to identify new 
antiviral therapies. The viral ribonucleoprotein (vRNP) is essential for viral 
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replication, making it an ideal target for antivirals. Essential activities of the vRNP 
include cap-snatching activity required for viral mRNA transcription and RNA 
polymerase activity required for viral mRNA transcription and RNA replication. 
The interactions required to form functional vRNPs with these essential activities 
comprise the most highly conserved protein domains within influenza A subtypes. 
These interaction domains represent ideal targets for small molecule inhibitors, 
as these domains are less likely to tolerate mutations. Combination drug therapy 
is also a potential means to challenge emerging antiviral resistance. The vRNP 
provides multiple viral protein targets to reduce selection pressures and 
emergence of resistant strains. However, if mutations conferring antiviral 
resistance are tolerated, history dictates these mutations will be selected by use 
of the antiviral and propagate in circulating influenza A viruses. This means the 
search for new influenza A antiviral inhibitors should be ongoing until a universal 
vaccine is achieved.  
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Figure 1. Antiviral Targets of Viral Ribonucleoprotein.  
Anti-influenza candidates include small molecule inhibitors that disrupt critical 
functions or interactions within the vRNP. This figure provides a summary of the 
promising anti-influenza candidates discussed in this review. Davis et al.: 
Emerging antiviral resistant strains of influenza A and the potential therapeutic 
targets within the viral ribonucleoprotein (vRNP) complex. Virology Journal 2014 
11:167. 
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Figure 2. Antiviral Targets of Nucleoprotein.  
Analysis of NP monomer crystal structure extracted from NP trimer crystal 
structure “2IQH” (Ye et al., 2006) using Deep View-Swiss-PdbViewer 4.0. 
Residue color determined by accessibility. Greatest to least accessible as 
follows: red, orange, yellow, green, light blue, and dark blue. Residue 289 is the 
proposed site of interaction with the antiviral compound nucleozin (Kao et al., 
2010). An intermolecular salt bridge formed by residues 339 and 416 of NP is 
essential for oligomerization and can be disrupted by small molecule inhibitors 
(Shen et al., 2011). Davis et al.: Emerging antiviral resistant strains of influenza A 
and the potential therapeutic targets within the viral ribonucleoprotein (vRNP) 
complex. Virology Journal 2014 11:167. 
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Figure 3. PA-PB1 Interaction Site is an Antiviral Target.  
Analysis of the PAC-PB1N crystal structure “3CM8” (He et al., 2008) using Deep 
View-Swiss-PdbViewer 4.0. Residues 1–16 of PB1 (red) are shown in interaction 
with residues 258–716 of PA (blue). Many small molecule inhibitors of PA 
resemble the N terminus of PB1 and bind in the hydrophobic pocket blocking 
essential interactions between the polymerase subunits (He et al., 2008, 
Ghanem et al., 2007, Fukuoka et al., 2012). Davis et al.: Emerging antiviral 
resistant strains of influenza A and the potential therapeutic targets within the 
viral ribonucleoprotein (vRNP) complex. Virology Journal 2014 11:167. 
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CHAPTER TWO 
MUTATIONAL ANALYSIS OF NUCLEOPROTEIN DOMAINS 
Identification and Development of Nucleoprotein Mutants 
Previous work in our lab investigated potential antiviral targets within NP 
by carefully analyzing the protein crystal structure (Ye et al., 2006) to identify 
accessible regions. The RNA binding pocket, head domain, and body domain 
(Fig. 4) were examined by amino acid substitutions created through cloning. The 
RNA binding pocket mutant, NPrbp1, encoded R152A while the head domain 
mutant, NPhd1 was altered at amino acids R213A and K214A. Five regions of 
the NP body domain were investigated through the following mutants: NPbd1 
(E46A, K48A), NPbd2 (D101A), NPbd3 (Y289G, K293G, E294G, Q308G, 
N309G), NPbd4 (S482A), and NPbd5 (S467G, E469G, N470G, T471G, and 
N472G).  
Viral Ribonucleoprotein Activity 
Activity of each NP mutant was tested using the reconstituted viral 
ribonucleoprotein (vRNP) expression system (Fig. 5). Plasmids to express mRNA 
encoding PB1, PB2, PA, and either NP, no NP, or NP mutant, were transfected 
into 293T cells along with plasmid to express Green Fluorescent Protein (GFP) M 
vRNA, the negative sense vRNA segment of the reconstituted vRNP. GFP 
positive cells within this system represent viral gene expression. GFP expression 
was observed 48 hours post transfection. All NP mutants expressed GFP at 
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similar levels as wild type NP (WT-NP) except NPbd3, the third of five body 
domains mutants constructed (Table 1 and Fig. 6). NPbd3 was investigated 
further for this master’s thesis.  
I next examined the activity of reconstituted vRNPs comprised of NPbd3 
at the level of RNA. The defect in viral protein expression observed with NPbd3 
is reflected at the RNA level. To directly examine both viral plus sense RNA 
synthesis (c/mRNA) and the second step in replication, negative sense RNA 
synthesis (vRNA), the reconstituted expression system was carried out with 
either an influenza M cRNA or M vRNA template. RNA was isolated from cells, 
DNAse treated, reverse transcribed with oligo dT (vRNA template) or vRNA 
specific primer (cRNA template), and subjected to qPCR analysis targeting the M 
gene. NPbd3 was found to be defective for viral c/mRNA synthesis as compared 
to WT-NP (Fig. 7) and vRNA synthesis when compared to the relative expression 
of WT-NP (Fig. 7).  
  
 28 
 
 
Figure 4. Domains of NP.  
Analysis of NP monomer crystal structure (Ye et al., 2006) colored by 
accessibility using Deep View-Swiss-PdbViewer 4.0. Greatest to least accessible 
as follows: red, orange, yellow, green, light blue, and dark blue.   
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Figure 5. Reconstituted Ribonucleoprotein Expression System.  
pcDNA expression vectors of PB1, PB2, PA, and NP or mutant are transfected 
into 293T cells to express RNPs. A pHH21 expression vector containing a 
genomic cRNA or vRNA template is also transfected. Cellular RNA polymerase I 
drives expression of the cRNA or vRNA template from pHH21. Cellular RNA 
polymerase II drives expression of viral mRNAs from pcDNA3 encoding 
plasmids.  
PB1 PB2 PA NP or 
Mutant 
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Table 1. NP Mutant Analysis.  
 
Seven NP mutants in regions of the RNA binding pocket, body domain, or head 
domain were constructed and tested for GFP activity in the reconstituted RNP 
expression system. (Laura Newcomb)  
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Figure 6. NPbd3 is Defective for Viral Protein Expression.  
Plasmids to express reconstituted vRNPs with GFP-M vRNA and either WT-NP, 
no NP, or NPbd3 were transfected into 293T cells. 48 hours post transfection 
cells were observed for GFP-M expression. WT-NP represents the positive 
control while no NP is the negative control. GFP was visualized with a Nikon 
Eclipse TS100 (Nikon Intensilight C-HGFI for fluorescence) inverted microscope 
and images captured with the Nikon DS-Qi1Mc camera with NS Elements 
software. 
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Figure 7. NPbd3 is Defective for Viral RNA Expression.  
RNA was purified from cells expressing reconstituted vRNPs or cRNPs as 
indicated. 1 µg was DNase treated and subject to reverse transcription with oligo 
dT and quantitative PCR with gene specific primers to calculate relative M RNA 
expression in each sample. Data are from triplicate trials; asterisks indicate 
p<0.02.  
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CHAPTER THREE 
CHARACTERIZATION OF NUCLEOPROTEIN BODY DOMAIN MUTANT #3 
Background 
The amino acid substitutions in NPbd3 were selected for mutagenesis to 
target interaction between NP and RdRP (Biswas et. al., 1998). The amino acids 
chosen were based on relative sequence conservation (Fig. 8) and accessibility 
in regards to the surface of the protein (Fig. 9) determined by examining the cryo-
electron microscopy (cryo-EM) structure of mini-vRNPs (Coloma et. al., 2009) 
and NP crystal structure (Ye et. al., 2006). Of seven NP mutants constructed, 
NPbd3 was the only mutant to be completely defective for protein expression in a 
reconstituted vRNP assay and was also found to be defective in viral RNA 
synthesis. These results highlighted the importance of the substituted amino 
acids and led to the characterization of NPbd3.  
Viral Ribonucleoprotein Activity 
Expression and Localization 
To ensure NPbd3 was expressed and localized as WT-NP cellular 
fractionation and Western blot were performed. Cells were collected and 
fractionated using non-ionic detergent and centrifugation as in materials and 
methods. Cellular fractions were analyzed by Western blot using anti-FLAG and 
anti-Hsp90 antibodies. NPbd3 is expressed and localized as WT-NP (Fig. 10). To 
further confirm localization of NPbd3, NP-GFP and NPbd3-GFP fusion proteins 
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were constructed and observed through fluorescence microscopy. Again NPbd3 
was localized in a pattern similar to WT-NP 48 hours post transfection (Fig. 11).  
NPbd3 was expressed at a slightly lower level than WT-NP in many of our 
location experiments (Fig. 10). To verify that NP is expressed in excess in the 
reconstituted vRNP assay and confirm decreased expression of NPbd3 was not 
responsible for the defect observed, we titrated WT-NP expressing plasmid in 
transfection from 600 nanograms to 100 nanograms. As expected, lowering 
plasmid amount during transfection did result in decreased NP protein 
expression (Fig. 12). Titration activity was examined in the reconstituted 
expression system using a GFP MvRNA template and confirms that even 
transfection of 100ng DNA plasmid resulted in little change in GFP expression 
(Fig. 13). While 100ng of NP expression plasmid and 600ng NPbd3 expression 
plasmid result in similar NP protein expression (Fig.12), they do not have similar 
vRNP activity as represented by GFP expression (Fig. 13). These experiments 
confirm NP is in excess in our standard reconstituted vRNP assay and that the 
lower NPbd3 expression is not the cause of the lack of activity. 
RNA Binding and Oligomerization 
NP binds viral RNA and through oligomerization provides the basic 
structure for the vRNP. There is one NP monomer for approximately 24 
nucleotides of RNA (Ye et. al., 2006). To confirm NPbd3 did not result in a defect 
in RNA binding, we performed an electrophoretic mobility shift assay (EMSA). 
WT-NP and NPbd3 were immunopurified with FLAG antibody coupled to agarose 
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beads. Immunopurified NP proteins were analyzed by SDS-PAGE and 
Coomassie Blue stain to ensure no additional protein contaminants (Fig. 14). 
Incubation of purified proteins with biotin labeled single stranded nucleic acid 
followed by non-denaturing Native PAGE and Western blot with HRP- 
Streptavidin confirmed NPbd3 bound nucleic acids as WT-NP (Fig. 14A). The 
Coomassie Blue stain shows a great deal of purified WT-NP but very little NPbd3 
(Fig. 14B), which is reflected in the amount of nucleic acid bound. Although there 
is a difference in the expression and concentration of protein, we can conclude 
NPbd3 binds nucleic acid. Additionally, a preliminary gel shift demonstrated 
equal amounts of WT-NP and NPbd3 binding nucleic acid but contained a great 
deal of background. NP oligomerization is important for RNA binding and 
formation of functional vRNPs. To examine NP oligomer formation, protein 
extracts from cells expressing WT-NP or NPbd3 were separated by blue native 
polyacrylamide gel electrophoresis (BN-PAGE) followed by western blot with 
anti-FLAG antibody. Results demonstrate the ability of WT-NP and NPbd3 to 
form oligomers (Fig. 15).  
Although NPbd3 was expressed in the cell, localized as WT-NP, found in 
oligomers, and bound nucleic acid in vitro, NPbd3 was defective for viral RNA 
expression in reconstituted vRNPs and cRNPs. I next decided to further define 
the important residues within this domain of NP.  
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Figure 8. Sequence Alignment of NPbd3 Residues. 
Percent conservation and consensus amino acids of NPbd3 are denoted with 
asterisks. Amino acid 289, 293, 294, 308, and 309 are highly conserved in the 
influenza strains utilized in the sequence alignment. (Laura Newcomb). 
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Figure 9. NP Body Domain Substitutions of NPbd3.  
Deep View-Swiss-PdbViewer 4.0 was used to analyze accessible residues in the 
body domain of the NP monomer crystal structure (Ye et al., 2006). Residues 
289, 293, 294, 308, and 309 were mutated in NPbd3 and are highlighted here. 
Residue color determined by accessibility. Greatest to least accessible as 
follows: red, orange, yellow, green, light blue, and dark blue.  
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Figure 10. NPbd3 is Expressed and Localized as WT-NP.  
Cells expressing reconstituted vRNPs were collected and fractionated with NP-
40 non-ionic detergent to break open cellular plasma membrane. Microscopy 
was used to confirm disrupted plasma membranes and intact nuclei. Nuclei were 
pelleted by centrifugation and proteins isolated. Proteins were separated on a 
10% SDS PAGE and transferred to nitrocellulose. Western blot was performed 
with anti-FLAG to detect WT-NP and NPbd3 and anti-Hsp90 to detect Hsp90, a 
protein localized in the cytoplasm, which serves as confirmation of cellular 
fractionation.  
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Fig. 4A 
Fig. 4B 
Figure 4. NPbd3 is expressed and localized as WT-NP. 
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Figure 11. NPbd3 is Localized as WT-NP.  
NP-GFP, NPbd3-GFP, or eGFP were expressed in cells grown on poly-L-Lysine 
cover slips. Cells were washed and fixed using a 1:1 methanol and acetone 
mixture. The coverslips were mounted onto glass slides using SouthernBiotech™ 
Dapi-Fluoromount-G™ Clear Mounting Media which stains the cell nucleus blue. 
Slides were observed on a Nikon ECLIPSE TE2000-U fluorescent microscope 
and images were captured with an Andor Clara DR-3446 camera using NIS-
Elements AR software.  
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Figure 12. Low Levels of NP Support Viral Ribonucleoprotein Formation.  
Total protein from titration samples was isolated and run on a 10% SDS PAGE 
and transferred to nitrocellulose. The membrane was probed with anti-FLAG to 
identify NP and anti-Tubulin as the loading control.  
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Figure 13. NP Titration Displays Activity at Lower Plasmid Concentration.  
Plasmids to express reconstituted vRNPs with GFP-M vRNA and either WT-NP, 
no NP, or NPbd3 at the concentrations listed above were transfected into 293T 
cells. 48 hours post transfection cells were observed for GFP-M expression. WT-
NP (400 ng) represents the standard concentration used in our experiments and 
positive control while no NP is the negative control. GFP was visualized with a 
Nikon Eclipse TS100 (Nikon Intensilight C-HGFI for fluorescence) inverted 
microscope and images captured with the Nikon DS-Qi1Mc camera with NS 
Elements software. 
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Figure 14. NPbd3 Maintains Nucleic Acid Binding.  
A. WT-NP and NPbd3 were immunopurified using anti-FLAG agarose beads. 
Purified WT-NP and NPbd3 were incubated with biotin labeled single stranded 
DNA and separated on an 8% PAGE TBE non denaturing gel before transfer to 
nitrocellulose. Biotin ssDNA was detected by interaction with Streptavidin-HRP 
and ECL reagents. No NP samples serve as the negative control. B. 
Immunopurified WT-NP and NPbd3 were run on a 10% denaturing gel and 
stained with Coomassie Blue.  
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Figure 6. NP RNA binding and Oligmerization. 
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Figure 15. NPbd3 Forms Oligomers as WT-NP.  
Blue Native Gel Electrophoresis was utilized to migrate protein extracts followed 
by western blot with anti-FLAG antibody to demonstrate NP oligomer formation. 
(Laura Newcomb and Jose Ramirez).  
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Figure 6. NP RNA binding and Oligmerization. 
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CHAPTER FOUR 
NUCLEOPROTEIN BODY DOMAIN SINGLE MUTANT ANALYSIS 
Background 
To investigate the NP body domain further, single amino acid glycine 
substitution mutants were cloned, Y289G, K293G, E294G, Q308G, and N309G. 
This method was conducted to conclude whether a single amino acid substitution 
was solely responsible for the defect observed in NPbd3.  
Viral Ribonucleoprotein Activity 
Single amino acid mutants were analyzed for vRNP function by assessing 
GFP expression using our reconstituted vRNP expression system with GFP-M 
vRNA (Fig. 5). All five single NP mutants displayed activity similar to WT-NP (Fig. 
16). Protein analysis showed the NP single mutants were expressed at levels 
similar to WT-NP (Fig. 17). RNA analysis of the M gene through reverse 
transcription using oligo-dT primers and qPCR revealed levels of viral mRNA 
expression with no statistical difference compared to WT-NP (Fig. 18). Therefore, 
our analysis of NP single substitutions within this region of the body domain 
revealed that all were nearly as functional as WT-NP, suggesting these 
accessible amino acids play a redundant role.  
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Figure 16. NP Single Amino Acid Mutants Result in Expression of Viral Protein.  
Cells expressing reconstituted vRNPs with GFP-M vRNA were visualized for 
GFP expression with a Nikon Eclipse TS100 (Nikon Intensilight C-HGFI for 
fluorescence) inverted microscope and images captured with the Nikon DS-
Qi1Mc camera with NS Elements software.  
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Figure 7. NP body domain single amino acid mutants display near wild type  
activity in vRNP assay. 
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Figure 17. NP Single Mutants are Expressed as WT-NP.  
Total protein was isolated from cells expressing reconstituted vRNPs with GFP-M 
vRNA template and WT-NP, no NP, or NP mutant.  Total protein extract was 
separated on 10% SDS PAGE and transferred to nitrocellulose. WT-NP, NPbd3, 
and NP single mutants were detected with anti-FLAG. Anti-tubulin was used as 
loading control. 
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Figure 18. NP Single Mutants Show No Significant Defect in Viral RNA 
Expression.  
RNA from cells expressing reconstituted vRNPs with FLAG-M vRNA and either 
WT-NP, no NP, NPbd3, or the single amino acid NP mutants were isolated. One 
microgram of RNA was treated with DNase before being reverse transcribed with 
oligo dT (mRNA) and analyzed through qPCR with primers targeting the M gene. 
qPCR reactions were carried out in triplicate. Significance was evaluated through 
t-test by comparing to WT-NP; asterisks indicate p-values <0.01.  
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CHAPTER FIVE 
NUCLEOPROTEIN BODY DOMAIN DOUBLE MUTANT ANALYSIS 
Background 
Single amino acid substitutions within the region of NPbd3 resulted in 
functional proteins that acted as WT-NP. These results prompted the creation of 
combinational mutations consisting of two amino acid substitutions with the goal 
of identifying an NP double mutant with a significant defect in activity.  
Viral Ribonucleoprotein Activity 
Amino acid pairs were substituted within this region of the NP body 
domain to further define which residues contribute to the defect observed. Four 
body domain double mutants were constructed, Q308G/N309G, Y289G/E294G, 
Y289G/N309G, and K293G/E294G. The pairs of double mutants were designed 
based on the relative proximity of the two amino acids to each other using the NP 
crystal structure (Fig. 9). These double mutants were analyzed for vRNP function 
by assessing GFP expression using our reconstituted vRNP expression system 
with GFP-M vRNA (Fig. 5). All NP double mutants showed statistically less GFP 
expression than WT-NP (Fig. 19). Total protein analysis by Western blot revealed 
that all NP double mutants are expressed as WT-NP (Fig. 20). RNA analysis of 
the M gene through reverse transcription using oligo-dT primers and qPCR 
revealed a significant decrease in viral mRNA expression in all double mutants 
compared to WT-NP (Fig. 21). Analysis of NP double mutants supports the 
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defect in viral RNA expression observed with NPbd3 is likely caused by a 
combination of multiple accessible amino acids in the NP body domain.  
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Figure 19. NP Double Amino Acid Mutants Result in Varied Expression of Viral 
Protein.  
Cells expressing reconstituted vRNPs with GFP-M vRNA were visualized for 
GFP expression with a Nikon Eclipse TS100 (Nikon Intensilight C-HGFI for 
fluorescence) inverted microscope and images captured with the Nikon DS-
Qi1Mc camera with NS Elements software.  
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Figure 20. NP Double Mutants are Expressed as WT-NP.  
Total protein was isolated from cells expressing reconstituted vRNPs with GFP-M 
vRNA template and the indicated NP mutant. Total protein extract was separated 
on 10% SDS PAGE and transferred to nitrocellulose. WT-NP, NPbd3, and NP 
double mutants were detected with anti-FLAG. Anti-tubulin was used as loading 
control.  
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Figure 21. NP Double Amino Acid Mutants Show Defect in Viral RNA Expression.  
RNA from cells expressing reconstituted vRNPs with FLAG-M vRNA and either 
WT-NP, no NP, NPbd3, or the double amino acid NP mutants were isolated. One 
microgram of RNA was treated with DNase before being reverse transcribed with 
oligo dT (mRNA) and analyzed through quantitative PCR with primers targeting 
the M gene. qPCR reactions were carried out in triplicate. Significance was 
evaluated through t-test by comparing WT-NP; asterisks indicate p-values <0.02.  
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CHAPTER SIX 
INTERACTION STUDIES OF NP AND PB2 
In order to directly determine NPbd3 interaction with the viral polymerase 
co-immunoprecipitation from cellular extracts were performed. Since avian 
influenza virus passaged in human cells resulted in virus with one amino acid 
change at residue 309 of NP consistently paired with changes in amino acid 627 
of the PB2 subunit of the RdRP (Danzy et. al., 2014), we focused our initial 
assessment on the NP-PB2 interaction. To facilitate studies with PB2, a C-
terminal STREP tagged PB2 protein was constructed through cloning (Rameix-
Welti et al., 2009). The construct was confirmed by sequencing and tested for 
activity in a reconstituted vRNP assay (Fig. 22). Additionally a Western blot was 
performed to identify the presence of the Strep epitope tag (Fig. 23). Although 
the insert of the plasmid was confirmed by sequencing several times, the STREP 
antibody never successfully bound to PB2 C-STREP.  
An alternative approach was then taken using Anti-FLAG M2 Affinity Gel 
agarose beads for immunopurification and a PB2 antibody to assess NP and 
PB2 interaction. WT-NP and PB2, 293/294 NP and PB2, WT-NP alone, 293/294 
NP alone, and PB2 alone were transfected in to 293T cells (Table 6). 
Immunopurified proteins were run on a denaturing gel, transferred to 
nitrocellulose and probed with anti-PB2 (Fig. 24). The blot was stripped and also 
probed with Anti-FLAG (Fig. 24). When comparing the eluted fraction of WT-
NP/PB2 and 293/294/PB2 there is less PB2 pulled down in the presence of the 
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293/294 NP mutant. The amount of PB2 pulled down and eluted in the 293/294 
NP with PB2 sample is similar to the PB2 alone, which serves as a background 
control. However, the amount of eluted 293/294 NP mutant is also less than WT-
NP. No definitive conclusions can be drawn from this trial but this work serves as 
preliminary interaction data and demonstrates we should be able to repeat this 
assay and obtain conclusive and repeatable results to determine whether or not 
NP-PB2 interaction is disrupted with NP mutants within the body domain.  
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Figure 22. PB2 C-STREP Activity.  
Cells expressing reconstituted vRNPs with WT PB2, no PB2, or PB2 C-STREP 
with GFP-M vRNA were visualized for GFP expression with a Nikon Eclipse 
TS100 (Nikon Intensilight C-HGFI for fluorescence) inverted microscope and 
images captured with the Nikon DS-Qi1Mc camera with NS Elements software. 
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Figure 23. STREP Epitope Not Detected in Western Blot.  
Total protein was isolated from cells expressing GFP-STREP control protein, 
PB2 C-STREP candidates, or vector. Total protein extract was separated on 10% 
SDS PAGE and transferred to nitrocellulose. STREP tagged proteins were 
detected with anti-STREP.  
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Figure 24. Co-Immunoprecipitation of NP and PB2.  
Cells expressing WT-NP and PB2, 293/294 NP and PB2, WT-NP alone, 293/294 
alone, or PB2 alone were fractionated and immunopurified. Eluate, flow through, 
and beads from each sample were run on a 10% SDS PAGE and transferred to 
nitrocellulose. The membrane was probed with anti-PB2, stripped, and probed 
with anti-FLAG. The three lanes of each sample contain the eluate, flow-through, 
and beads (left to right).   
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CHAPTER SEVEN 
SUMMARY AND DISCUSSION  
 
Mutational analysis of the NP body domain revealed a region of five amino 
acids that is essential for viral gene expression. NPbd3 encodes glycine at 5 
amino acids within an accessible region of the NP body domain. Cellular 
fractionation and Western blot, in addition to NP-GFP fusions and fluorescence, 
confirm NPbd3 was expressed and localized as WT-NP (Fig. 10 and 11). Gel 
shift (EMSA) with purified NP protein confirm NPbd3 bound nucleic acids as WT-
NP (Fig. 14). Blue Native Gel Electrophoresis demonstrated NPbd3 oligomerized 
(Fig. 15). Although NPbd3 was expressed, localized, and bound nucleic acid as 
WT-NP, we found NPbd3 was defective for RNA expression in reconstituted 
vRNPs and cRNPs as evaluated by reverse transcription and quantitative 
polymerase chain reaction (RT-qPCR).  
To investigate this region of the NP body domain further, single and 
double amino acid mutations were cloned. Analysis of NP single mutants 
revealed that all were nearly as functional as WT-NP for RNA expression in 
reconstituted vRNPs, suggesting these accessible amino acids in the NP body 
domain play a redundant role (Fig. 18). However, four different combinations of 
two amino acid mutations resulted in NP double mutants that displayed a 
significant defect in RNA expression in reconstituted vRNPs, confirming these 
accessible amino acids in the NP body domain play a significant role for viral 
RNA synthesis (Fig. 21). The greatest defect in mRNA synthesis observed was in 
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double mutant 293/294, followed by 308/309, 289/309, and 289/294. Although 
amino acid 293 is variable and 294 is conserved, a mutation at 294 alone was 
not sufficient to cause a defect and the defect observed with 289/294 was only 
minimal. In our assays, 294 coupled with a change at 293 resulted in the greatest 
observed defect in RNA synthesis. The glutamic acid at 294 has a negative 
charge while the lysine at 293 is positively charged. Perhaps these opposite 
charged residues provide an internal interaction important for supporting the 
activity occurring at this domain. Future mutational analysis to substitute a 
negatively charged residue at 293 and a positively charged residue at 294 may 
provide more insight in to the interactions in and around 293/294. The tyrosine at 
residue 289, glutamine at residue 308, and asparagine at residue 309 are 
moderately to highly conserved and polar: substituting a glycine at any two of 
these residues leads to a defect in mRNA synthesis.  
The body domain region designated for mutagenesis in NPbd3 was 
selected for probable interaction with the RdRP based on mini-replicon images 
(Coloma et al., 2009). While 294 and 293 may be involved in an internal NP 
interaction, we hypothesize that disruption of an essential NP interaction with the 
RdRP is the explanation for the RNA defect observed with mutations at 308/309 
and 289/309. In support of this, avian influenza virus passaged in human cells 
resulted in virus with one amino acid change at residue 309 of NP consistently 
paired with specific changes in amino acid 627 of the PB2 subunit of the RdRP 
(Danzy et. al., 2014). The double mutant displaying the most significant defect in 
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RNA synthesis, 293/294, was used in co-immunopreciptation trials with PB2 (Fig. 
24). Since this double mutant may not represent NP interaction with the 
polymerase, this experiment will be repeated with inclusion of analysis of 
308/309 and 289/309 in order to make a conclusion on the interaction between 
our body domain mutants and PB2. Future experiments are focused on obtaining 
a better co-immunoprecipitation gel image and running a blue native gel of 
vRNPs with small templates to assess vRNP formation directly as in Sanchez et 
al., 2014.  
I reason that this accessible body domain of NP is an important NP 
interaction surface and small molecule inhibitors could block access to this NP 
interaction, making this region a viable antiviral target. Indeed, two amino acids in 
this NP body domain, 289 and 309, comprise a novel groove implicated in 
binding the small molecule inhibitor nucleozin (Kao et. al., 2010). The influenza 
A(H1N1)pdm09 strains contained a rare polymorphism at residue 289 (Kao et. 
al., 2010). Instead of a tyrosine, these H1N1 strains contain a histidine at amino 
acid 289. Tyrosine has a large hydrophobic side chain while histidine has a 
smaller and positively charged side chain. This change likely disrupts the 
aromatic ring stacking between nucleozin and the tyrosine at 289 (Kao et. al., 
2010). Beyond this, another compound, FA-10 has shown efficacy against the 
A(H1N1)pdm09 strains but less activity toward wild-type WSN virus (Kao et. al., 
2010). These studies show that optimization of compounds targeting this domain 
could lead to an effective antiviral drug. The work presented here has defined 
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this domain with greater clarity, providing evidence that the polar amino acids 
289, 308, and 309 provide one target while the charged interaction at 293 and 
294 is likely a separate target; perhaps both regions of the domain can be 
targeted in a combinational therapeutic approach. This thesis demonstrates that 
disruption of this accessible domain should block viral RNA expression and 
support additional studies of novel antivirals targeting this conserved NP body 
domain. 
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CHAPTER EIGHT 
MATERIALS AND METHODS 
Nucleoprotein Body Domain Mutant Construction 
First Step PCR 
Polymerase chain reactions (PCR) were carried out in a total of 50 µl with 
Thermo Scientific Phusion High-Fidelity DNA polymerase master mix at a 1X 
concentration, 50 picomoles (pmol) of each primer, 200 ng of pcDNA NP-FLAG 
DNA, and sterile water up to volume.  
Table 2. First Step PCR Conditions 
Reaction Primers Cycling Conditions 
Reaction A: 
Large fragment 
5’ EcoRI NP and 3’ 
Mutant primer 
Initial denaturation: 95 °C for 60 
seconds. 
Denature: 95 °C for 30 seconds.  
Anneal: 60 °C for 40 seconds.  
Extend: 72 °C for 150 seconds. 
25 cycles. 
Reaction B: 
Small Fragment 
5’ Mutant primer and 3’ 
Xbalstop1XFLAG 
Same as above. 
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Table 3. Primer Sequences 
Construct 
Name 
Primer 
Name 
Sequence (5’ to 3’) 
NPbd3 NP5X289-
309-F 
GGCGACTTCGAAGGAGGAGGATACTC
TTTAGTGGGAATAGACCCTTTCAAACT
ACTTGGAGGCAGCCAAG 
 NP5X289-
309-R 
GCCTCCAAGTAGTTTGAAAGGGTCTAT
TCCCACTAAAGAGTATCCTCCTCCGAA
GTCGCCCCCACTG 
Y289G 289G-F GCCAGTGGGGGCGACTTCG 
 289G-R CGAAGTCGCCCCCACTGGC 
K293G 293G-F TACGACTTCGAAGGAGAGGGATACTCT 
 293G-R AGAGTATCCCTCTCCTTCGAAGTCGTA 
E294G 294G-F GACTTCGAAAAAGGAGGATACTC 
 294G-R GAGTATCCTCCTTTTTCGAAGTC 
Q308G 308G-F CCTTTCAAACTACTTGGAAACAGC 
 308G-R GCTGTTTCCAAGTAGTTTGAAAGG 
N309G 309G-F CTACTTCAAGGCAGCCAAGTATAC 
 309G-R GTATACTTGGCTGCCTTGAAGTAG 
Y289G/E294G 289/294-F GGGGGCGACTTCGAAAAAGGAGG 
 289/294-R CCTCCTTTTTCGAAGTCGCCCCC 
K293G/E294G 293/294-F TACGACTTCGAAGGAGGAGGATACTCT
TTAGTGGGAATAGACCCTTTCAAACTA
CTTCAAAAC 
 293/294-R GTTTTGAAGTAGTTTGAAAGGGTCTATT
CCCACTAAAGAGTATCCTCCTCCTTCG
AAGTCGTA 
Q308G/N309G 308/309-F CCTTTCAAACTACTTGGAGGCAGC 
 308/309-R GCTGCCTCCAAGTAGTTTGAAAGG 
Y289G/Q309G 289/309-F GGCGACTTCGAAAAAGAGGGATACTCT
TTAGTGGGAATAGACCCTTTCAAACTA
CTTCAAGGC 
 289/309-R GCCTTGAAGTAGTTTGAAAGGGTCTAT
TCCCACTAAAGAGTATCCCTCTTTTTCG
AAGTCGCC 
Restriction 
Enzyme End 
Primers 
Primer 
Name 
Sequence (5’ to 3’) 
EcoRI 5’ EcoRI 
NP 
TATGAATTCATGGCGTCCCAAGGC 
XbaI 3’ 
Xbalstop1
XFLAG  
GACTCTAGATTAACCGTCATGGTCTTT
GTAGTCCGCCGCATTGTCGTACTCC 
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Agarose Gel Extraction. PCR products were run on a 1% agarose gel for 
55 minutes at 120 volts (V) and 400 milliamps (mA) to separate any remaining 
template DNA from desired product. The QIAquick® Gel Extraction protocol was 
followed except for the addition of isopropanol.  
Second Step PCR  
The next step in the construction required the combination of the small and large 
DNA fragments with the addition of restriction enzyme encoded end primers to 
obtain the entire desired insert. PCR reactions were carried out in a total of 50 µl 
with Thermo Scientific Phusion High-Fidelity DNA polymerase master mix at a 1X 
concentration, 100 ng of the large fragment, 70 ng of the small fragment, and 50 
pmol of each primer (5’ EcoRI NP and 3’ Xbalstop1XFLAG) which was added 
after 10 cycles of PCR. The ratio for the amount of each fragment needed for 
PCR was calculated by the following equation: (100ng Large fragment X Size of 
Small fragment)/ Size of Large fragment= ng of small fragment for every 100ng 
large fragment. The second PCR cycling conditions were as follows: Initial 
Denaturation: 95 °C for 60 seconds. Denature: 95 °C for 30 seconds. Anneal: 60 
°C for 40 seconds. Extend: 72 °C for 150 seconds. 25 cycles. (Primers added 
after 10 cycles).  
Confirmation Gel and PCR Purification. Five µl of the 2nd PCR reaction 
products, also referred to as the ‘insert’, were loaded on a 1% agarose gel and 
run for 55 minutes at 120V and 400mA. The remaining 45 µl of the PCR products 
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were purified following the QIAquick® PCR Purification protocol with an elution in 
30 µl. 
Digest with EcoRI and XbaI. 140 ng of the insert and 500 ng of pcDNA 
vector were separately digested with EcoRI (1:20 dilution), XbaI (1:20 dilution), 
1X Tango buffer, and water up to volume. The reactions were incubated 
overnight at 37 °C. The pcDNA vector was then phosphatase treated with 
Antarctic Phosphatase (1:10 dilution) and Antarctic Phosphatase buffer (1:10 
dilution) for 30 minutes at 37 °C. The insert and vector were heat inactivated at 
80 °C for 20 minutes.  
Ligation. Ligation reactions were carried out at the following vector to 
insert ratios: 1:1, 1:3, and 1:5. A vector only negative control was included. Each 
reaction tube included digested insert and vector DNA (except vector only 
control), T4 DNA Ligase (1:10 dilution), T4 DNA Ligase Buffer (1:10 dilution), and 
water up to volume. The reaction was incubated overnight at 4 °C.  
Transformation. Ligated plasmids were transformed into chemically 
competent E. coli cells. In addition to the 1:1, 1:3, 1:5, and vector ligations, a no 
DNA control and a positive pUC19 control were also transformed. The 
manufacturer’s protocol was followed for TransMax FB5α Competent Cells-10E9 
at a smaller volume of 25 µl of cells and 250 µl of S.O.C. medium. The 
transformed cells were spread onto Luria-Bertani (LB) agar plates containing 
ampicillin (at 100 mg/mL) and incubated over night at 37°C.  
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Colony PCR 
Candidate colonies on transformation plates were screened for the 
plasmid of interest using colony PCR. Individual colonies were picked with a 100 
µl pipet tip and used to introduce bacterial cells to a PCR master mix (50 pmol 5’ 
EcoRI NP and 3’ Xbalstop1XFLAG restriction enzyme end primers, 1X master 
mix for Promega Taq polymerase, and water) and also LB AMP liquid media 
(grown at 37°C overnight). The following PCR conditions were used: Initial 
Denaturation: 95°C for 60 seconds. Denature: 95°C for 30 seconds. Anneal: 
60°C for 40 seconds. Extend: 72°C for 150 seconds. 30 cycles. WT-NP was used 
as a positive control, while pcDNA vector was used as a negative control. The 
PCR products were run on a 1% agarose gel for 55 minutes at 120 V and 400 
mA. Candidates demonstrating a similar pattern to WT-NP were miniprepped 
using the QIAprep® Spin Miniprep protocol. 
Diagnostic Digest 
Candidate plasmids were subjected to a diagnostic digest. 400 ng of DNA 
was incubated with EcoRI (1:20 dilution), XbaI (1:20 dilution), 1X buffer, and 
water at 37°C for one hour. WT-NP was used as a positive control, while pcDNA 
vector was used as a negative control. Digested DNA was run on a 1% agarose 
gel for 55 minutes at 120 V and 400 mA.  Candidates displaying a pattern similar 
to WT-NP were sent out for sequencing using flanking and internal primers. 
Sequence analysis was carried out using Basic Local Alignment Search Tool 
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(BLAST). Plasmids containing the desired mutation were prepared for long term 
storage in 15% glycerol and stored at -80 °C. 
PB2 C-STREP  
Linearization of Template DNA 
  2,000 ng of pcDNA PB2 was digested with BamHI at a 1:10 dilution at 37 
°C for over night in order to linearize the template to be used in the first round of 
PCR. The digest was confirmed by migration on a 1% agarose gel for 50 minutes 
at 120 V and 400 mA.  
Table 4. Primers for PB2 C-STREP Construction 
Primer Name Sequence (5’ to 3’) 
BamHIPB2F CGCGGATCCATGGAAAGAATAAAAGAACTACGGAATCT
GATGTCGC 
XbalStrepPB2R ATATCTAGATTATTTCTCAAATTGTGGATGAGACCAAGC
TGCTGCATTGATGGCCATCCG 
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PB2 C-STREP PCR 
PCR reactions were carried out in a total of 50 µL with Thermo Scientific 
Phusion High-Fidelity DNA polymerase master mix at a 1X concentration, 50 
pmol of each primer, 200 ng of linearized pcDNA PB2 DNA, and sterile water up 
to volume. PB2 C-STREP cycling conditions were as follows: Initial Denaturation: 
95 °C for 60 seconds. Denature: 95 °C for 30 seconds. Anneal: 70 °C for 40 
seconds. Extend: 72 °C for 150 seconds. 25 cycles.  
PCR product gel extraction, digest, ligation, transformation, colony PCR, 
diagnostic digest, and sequencing were performed in the same manner as the 
NP plasmid constructs. BamHI and XbaI restriction enzyme sites were utilized for 
PB2 C-STREP construction.  
Reconstituted Viral Ribonucleoprotein Activity Assay 
Cells  
293T human embryonic kidney cells were purchased from American Tissue 
Culture Collection and maintained at 37 ˚C with 5% CO2 in DMEM with 10% FBS.  
Reconstituted Ribonucleoprotein Expression System 
In order to reconstitute the influenza RNP expression system, pcDNA 
expression vectors of PB1, PB2, PA, and wildtype or mutant NP were transfected 
into 293T cells. A pHH21 GFP-MvRNA or pHH21 McRNA expression vector was 
used to express the coding RNA. Cellular RNA polymerase I drives expression of 
the cRNA or vRNA template from pHH21 encoding plasmids. Cellular RNA 
polymerase II drives expression of viral mRNAs from pcDNA3 encoding 
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plasmids. 
Table 5. Reconstituted Ribonucleoprotein Expression System  
Plasmid Nanograms of DNA (6 well plate) 
pcDNA PB1 400  
pcDNA WT PB2 400 
pcDNA PA 200 
pcDNA WT-NP 
OR No NP (Vector) 
OR pcDNA NP mutant 
600 
pHH21 GFP MvRNA 
OR pHH21 McRNA 
400 
 
 
Transfection 
Preparation for transfection began by incubating a lipid-based Trans-IT 
reagent (DNA to reagent ratio of 1:3 per plasmid mixture) with 250 µl of 
serumfree media (per plasmid mixture) for five minutes at room temperature. The 
transfection mixture was then added to the plasmid mixture containing tubes, 
flicked to mix, and incubated for 15 minutes at room temperature. The mixture of 
plasmids, reagent, and media were then added drop wise into 293T cells at 65 
percent confluency. Cells were incubated in a tissue culture incubator for 48 
hours.  
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Green Fluorescent Protein Visualization 
Cells were observed for GFP-M expression 48 hours post transfection. 
WT-NP was the positive control while no NP is the negative control. GFP was 
visualized with a Nikon Eclipse TS100 (Nikon Intensilight C-HGFI for 
fluorescence) inverted microscope and images captured with the Nikon DS-
Qi1Mc camera with NS Elements software. 
Cell Collection 
Cells were collected and pelleted by centrifugation 48 hours post-
transfection. Proteins were isolated through either total protein isolation or 
cellular fractionation.  
Total Protein Isolation  
Cell pellets were resuspended in RIPA Lysis Buffer (25 mM HCl pH 7.6, 
150 mM NaCl, 1% deoxycholate, 0.1% SDS) containing protease inhibitors and 
lysed using a Fisher Scientific Sonic Dismembrator for 10 pulses at 30%, output 
3-4. Proteins were denatured using 1X SDS protein loading dye and boiling for 
five minutes. Proteins were separated on a 10% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS PAGE) and transferred to nitrocellulose. 
All NP constructs contain a FLAG epitope tag and were detected using anti-
FLAG. Anti-tubulin was used to confirm even protein loading when evaluating 
total protein.  
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Cellular Fractionation 
Cells were fractionated using 10% NP-40 non-ionic detergent to break 
open cellular plasma membrane while keeping the nuclear membranes intact. 
Microscopy was used to confirm disrupted plasma membranes and intact nuclei. 
The nuclei were pelleted by centrifugation and sonicated for 30 pulses at 30% to 
bust the nuclear membrane. Both nuclear and cytoplasmic fractions were 
clarified by high-speed centrifugation.  
Immunopurification  
The nuclear fraction of cells transfected with WT-NP, NPbd3, or No NP 
were incubated with Anti-FLAG M2 Affinity Gel agarose beads (Sigma-Aldrich), 
incubated overnight at 4°C with rotation, washed five times in RSB (reticulocyte 
standard buffer: 10mM Tris HCl pH 7.5, 10mM KCl, 1.5mM MgCl2) + 0.2% NP-
40, and eluted with 150 ng/ul 3X FLAG peptide (APEXBIO). The elutant was 
separated on a 10% SDS PAGE and stained with Coomassie Blue overnight to 
check purity.   
Gel Shift 
Immunopurified proteins were incubated with 20 picomoles of biotin-
labeled ssDNA for 20 minutes at room temperature and mixed with 2.5% glycerol 
for loading. The protein-DNA samples were run on an 8% TBE non-denaturing 
PAGE in 4°C, followed by transfer to nitrocellulose and Western blotting. The 
membrane was probed with Streptavadin-HRP (1:3,000) and Pierce ECL 
reagents were used to detect the biotin labeled ssDNA.  
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Blue Native Polyacrylamide Gel Electrophoresis  
Total protein from WT-NP, NPbd3, or no NP transfected cells were run on 
a 6% 1D Blue Native PAGE (Lin et al., 2012) and transferred on to nitrocellulose. 
The blot was probed with anti-FLAG to detect WT-NP and NPbd3.  
RNA Isolation 
Total RNA was isolated with Trizol (Invitrogen), following the 
manufacturer’s protocol. RNA concentration and purity of samples was 
determined at OD260 and OD280 using a NanoDrop ND1000 
Nanospectrophotometer (Thermo Fischer Scientific). Integrity of rRNA was 
evaluated on a 1% bleach/1% agarose gel (Aranda et. al., 2012). 
RTqPCR 
2.5 µg of RNA was DNase treated. 1 µg was reverse transcribed using 
Promega AMV reverse transcription system following the manufacturer’s 
protocol. 1 µg was used in the negative control reaction, lacking the AMV reverse 
transcriptase enzyme to control for DNA contamination. Oligo dT (mRNA) or 
vRNA specific primers (vRNA) were used in the RT reaction to produce cDNA. 
Real time quantitative PCR using an Applied Biosystems SYBR Select Master 
Mix was performed on cDNA with primers targeting the influenza M gene. qPCR 
reactions were carried out in triplicate using the AB Step One qPCR machine. 
Significance was evaluated through t-test by comparing WT-NP with no NP or 
NPbd3 both reporting significance with p-values <0.02.  
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Green Fluorescent Protein Fusion Location 
Plasmids expressing NP-GFP, NPbd3-GFP, or eGFP were transfected 
into 293T cells grown on poly-L-Lysine cover slips. 48 hours post transfection the 
cells were washed and fixed using a 1:1 methanol and acetone mixture. The 
coverslips were mounted onto glass slides using SouthernBiotech™ Dapi-
Fluoromount-G™ Clear Mounting Media, which stains the cell nucleus blue. 
Slides were observed on a Nikon ECLIPSE TE2000-U fluorescent microscope 
and images were captured with an Andor Clara DR-3446 camera using NIS-
Elements AR software. Plasmids NP-GFP and NPbd3-GFP were constructed by 
Alan Santana 
Testing PB2 C-STREP for Activity 
293T cells were transfected following the guidelines in Table 5. GFP 
images were captured using Nikon Eclipse TS100 (Nikon Intensilight C-HGFI for 
fluorescence) inverted microscope and images captured with the Nikon DS-
Qi1Mc camera with NS Elements software. Total protein was isolated and 
separated on a 10% SDS gel and transferred to nitrocellulose. PB2 C-strep was 
detected using an anti-STREP antibody (IBA-LifeSciences).  
Co-Immunoprecipitation 
293T cells were transfected according to Table 6. Cells were collected, 
fractionated, and immunopurified as described above. Eluted proteins were run 
on a 10% SDS PAGE, transferred to nitrocellulose, and probed with anti-PB2 
(GeneTex). The blots were stripped and probed again with anti-FLAG.  
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Table 6. Co-Immunoprecipitation Transfection 
Sample NP amount  PB2 amount  
WT-NP/PB2 1,000 ng 9,000 ng 
293:294/PB2 1,000 ng 9,000 ng 
WT-NP only 1,000 ng 0 
293:294 only 1,000 ng 0 
PB2 only 0 9,000 ng 
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